| India | Thailand | Turkey | |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from AUD $13,203 | from AUD $41,694 | from AUD $9,034 |
No hidden fees – just official clinic prices. Pay at the clinic for Сarcinomatosis treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Сarcinomatosis treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Сarcinomatosis treatment journey.
Dr Shruti Kate trained at the prestigious Tata Memorial Hospital, where she served as a consultant in the medical oncology department.
Professor Nagarkar has performed over 50,000 cancer surgeries and leads the HCG Manavata Cancer Centre. He trained at the prestigious Tata Memorial Hospital in Mumbai.
Professor Sridhar P.S. is a leading specialist in radiation oncology at HCG Manavata Cancer Centre with over two decades of clinical experience. He focuses on modern radiotherapy techniques to manage complex secondary tumours spread throughout the body.
Specialists in India achieve the best results using Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). This intensive approach removes visible tumours before applying heated chemotherapy to the abdomen. Leading JCI-accredited hospitals in Bengaluru and Gurgaon report high success using this gold-standard protocol.
Bookimed Expert Insight: Indian cancer centres like HCG Manavata provide a distinct advantage for complex cases. They combine high-volume surgical expertise with US-FDA audited research. Some clinics focus on surgery. Those with dedicated nuclear medicine departments can track microscopic spread more accurately. This dual focus often leads to better-tailored immunotherapy plans for stage 4 patients.
Patient Consensus: Patients in India emphasise that getting genetic mapping early helps doctors choose between standard chemotherapy and targeted drugs. Many find support services like airport transfers and visa help essential for managing a long treatment stay.
Indian oncology centres report success rates for CRS and HIPEC comparable to international benchmarks. Major facilities achieve complete tumour removal in over 90% of cases. Data indicates a 5-year survival rate of approximately 37.7% for suitable candidates across various peritoneal malignancies.
Bookimed Expert Insight: Success in India is driven by high-volume centres that integrate specialised diagnostics with surgery. HCG Manavata Cancer Centre uses PET-CT and US-FDA audited research to refine patient selection. This intensive screening means only patients likely to benefit undergo the 10-hour procedure. This protects overall survival statistics.
Patient Consensus: Patients note that recovery takes 3 to 6 months in India. Even so, the surgery offers a significant life-extending opportunity. Many emphasise that reaching a low PCI score through prior chemo is vital for the best results.
India hosts elite surgical oncologists specialising in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Leading experts include Dr Raj Nagarkar at HCG Manavata Cancer Centre. Other specialists are based at Manipal Hospitals. These experts treat peritoneal carcinomatosis using robotic systems and heated chemotherapy protocols.
Bookimed Expert Insight: Many Australian patients look to major cities like Delhi. However, Nashik has emerged as a high-volume oncology hub. HCG Manavata Cancer Centre in Nashik serves 75,000 patients annually and manages 65,000+ surgeries. This massive caseload gives surgical teams exceptional experience with rare peritoneal cancers, surpassing smaller private clinics.
Patient Consensus: Patients in India recommend consulting both medical and surgical oncologists for Stage 4 cases. They suggest using genetic tumour sequencing to guide immunotherapy and targeted treatment paths.
Indian oncology centres treat carcinomatosis without surgery using systemic chemotherapy, immunotherapy, and targeted drugs. These approaches manage advanced cancer and improve quality of life. Specialist facilities in India use genetic sequencing. They select the most effective non-surgical therapies for individual patients.
Bookimed Expert Insight: Surgery is standard for carcinomatosis. However, Indian centres like HCG Manavata Cancer Centre lead in non-surgical expertise. Dr Shruti Kate specialises in immunotherapy and metronomic therapy. These are vital for patients unsuitable for theatre. This focused expertise often helps achieve long-term disease stability. It can work even when a cure is unlikely.
Patient Consensus: Patients in India find tumour sequencing essential for effective oral chemo options. They emphasise that professional symptom management through palliative care significantly improves daily life. This is particularly important when surgery is ruled out.
Recovery from carcinomatosis treatment in India typically requires 3 months. This is the time needed for physical recovery after major surgery like HIPEC. Patients starting systemic chemotherapy usually follow cycles lasting 3 to 6 months. India offers rapid access to oncology specialists. This often allows surgery scheduling within 4 days of diagnosis.
Bookimed Expert Insight: Indian oncology centres like HCG Manavata Cancer Centre provide immense surgical depth. Prof. Dr Raj Nagarkar there has performed over 50,000 cancer surgeries personally. This high volume often leads to more efficient recovery protocols. This is in contrast to centres with less experience in complex peritoneal cases.
Patient Consensus: Patients note that India offers significantly faster scheduling for major procedures than Western countries. They also appreciate the high accessibility of doctors and quality care. However, they highlight that follow-up is a multi-year commitment.